Newer oral anticoagulants, or blood thinners, were linked to a lower risk of clinically relevant nonmajor bleeding than warfarin, an older blood thinner, in adults with sickle cell disease (SCD) treated for dangerous blood clots, according to a study led by researchers in Saudi Arabia. However, no significant differences…
News
Casgevy (exagamglogene autotemcel) will be reimbursed by Germany’s public health system, enabling people with severe sickle cell disease (SCD) in the country, ages 12 and older, to access the one-time gene-editing therapy at low or no cost. The reimbursement agreement, established with Vertex Pharmaceuticals — which developed…
Sickle cell disease (SCD) hospitalization patterns vary across New York State, with New York City showing the largest share of hospitalizations and Long Island reporting the highest charges for care, a recent study showed. In addition, longer hospital stays were seen in regions where access to specialized care may…
A discovery about red blood cells could have implications for sickle cell disease (SCD) and other blood disorders marked by problems with hemoglobin, the protein red blood cells use to carry oxygen through the bloodstream. Scientists found that red blood cells growing under stressful conditions can import heme, an…
Women with sickle cell anemia (SCA), the most common and severe form of sickle cell disease (SCD), have significantly lower ovarian reserve relative to women without SCA and with proven fertility, a study in Nigeria shows. Ovarian reserve is a marker-based estimate of the remaining supply of eggs in the…
One of the $3 million 2026 Breakthrough Prizes — in Life Sciences — has been awarded to two researchers whose discoveries reshaped the treatment of sickle cell disease (SCD). The award from the Breakthrough Prize Foundation, which counts its mission as “honoring scientists as heroes of our society,” is…
A global, late-stage clinical trial testing etavopivat in people with sickle cell disease (SCD) has hit its main goals, showing that the experimental oral therapy improved hemoglobin levels and reduced the risk of painful episodes compared with a placebo. Based on these positive results from the Phase 3…
People with sickle cell disease (SCD) who live in sub-Saharan Africa are less likely than those in other countries to use common medications to manage the condition, including over-the-counter pain-relieving medicines, a study found. These patients also tended to report a lower perceived disease burden than those in high-income…
Clinician bias toward people with sickle cell disease (SCD) may be tied to stigma around opioid use, rather than race or chronic pain alone, a new study suggests. “Although patients with sickle cell disease routinely use opioid medications to manage their chronic pain, the vast majority do not…
Children with sickle cell anemia (SCA), the most common and severe form of sickle cell disease (SCD), show signs of altered development in specific regions of the brain, even in children without a history of silent or overt stroke, a new study from the U.S. reports. Using an artificial…
Recent Posts
- Intense crises: When sickle cell pain becomes unbearable
- Newer blood thinners tied to less bleeding in sickle cell disease study
- New reimbursement deal in Germany expands access to Casgevy for SCD
- New York study finds regional gaps in sickle cell disease hospitalizations
- When a sickle cell pain crisis interrupts a stretch of good health, part 1
- Scientists discover how stressed red blood cells make hemoglobin
- How my sickle cell disease advocacy has evolved over time
- New study links sickle cell anemia to lower ovarian reserve in women
- $3M Breakthrough Prize honors duo whose work changed SCD treatment
- Etavopivat Phase 3 results support potential approval in sickle cell disease